Management of Heart Failure Medications During Acute Kidney Injury
The decision to discontinue heart failure medications during AKI should be highly selective and individualized based on specific clinical parameters—discontinue only when the drug is clearly causing the AKI or when true contraindications exist (cardiogenic shock, severe hypotension, advanced heart block for beta-blockers without pacemaker, or angioedema for ACEi/ARNi), as routine discontinuation is associated with significantly increased mortality.
Key Principle: Continuation Over Discontinuation
The evidence strongly challenges the traditional practice of routinely stopping heart failure medications during AKI. Discontinuation of guideline-directed medical therapy (GDMT) during AKI hospitalization is associated with worse outcomes 1, 2:
- Stopping ACEi/ARBs after AKI increases 30-day mortality by 1.96-fold 2
- Discontinuation of any GDMT during hospitalization increases mortality risk 1
- Failure to restart ACEi/ARBs post-surgery increased 30-day mortality, likely from hypertensive rebound causing acute cardiac decompensation 3
Algorithmic Approach to Medication Management
ACE Inhibitors/ARBs/ARNi
When to Consider Temporary Discontinuation:
- Cardiogenic shock (absolute contraindication until resolved)
- Symptomatic hypotension with end-organ hypoperfusion
- Severe hyperkalemia (K+ >6.0 mmol/L)
- Angioedema (absolute contraindication)
- Clear causal relationship established between the drug and AKI 3
When to CONTINUE Despite AKI:
- Mild, transient blood pressure reductions 1
- Mild deteriorations in renal function (≤20% decrease in eGFR) 1
- Asymptomatic creatinine rises during effective decongestion 4
- Stable hemodynamics with adequate perfusion
Critical Evidence: Despite sparse evidence supporting routine discontinuation 3, observational data from GWTG-HF registry showed that continuing ACEi/ARB reduced 30-day readmission (18% vs 24%) and mortality (7% vs 14%) compared to discontinuation 1. The risk-benefit calculation must account for the fact that hypotension and decreased filtration fraction are recognized effects that may be tolerable in chronic heart failure but require careful assessment in AKI 3.
Beta-Blockers
Strongly favor continuation unless:
- Cardiogenic shock requiring inotropic support
- Advanced heart block without pacemaker
- Marked volume overload with marginal cardiac output 1
Evidence for Continuation:
- Discontinuation associated with higher in-hospital mortality, short-term mortality, and rehospitalization 1
- Meta-analysis confirms increased mortality risk with beta-blocker withdrawal 1
- Beta-blockers do NOT cause acute reduction in eGFR or alter slope of eGFR decline 5
- Patients with lowest GFR actually had highest relative risk reduction with metoprolol in MERIT-HF 5
Critical Warning: Beta-blockers should NOT be stopped suddenly due to risk of rebound myocardial ischemia, infarction, and arrhythmias 6. Seek specialist advice before discontinuation.
Mineralocorticoid Receptor Antagonists (MRAs)
When to Discontinue:
- Severe hyperkalemia (K+ >6.0 mmol/L) - stop immediately 6
- Significant renal dysfunction (creatinine >310 μmol/L or eGFR <20 mL/min/1.73 m²) 6
When to Continue with Monitoring:
- K+ 5.5-6.0 mmol/L: halve dose and monitor closely 6
- Moderate renal dysfunction: continue with frequent biochemical monitoring
Evidence: In COACH study, continuation of spironolactone during hospitalization was associated with lower 30-day mortality and HF rehospitalization 1. However, real-world hyperkalaemia rates exceed trial rates, necessitating vigilant monitoring 5.
Diuretics
Paradoxical Finding: While diuretics are often reduced during AKI, the evidence shows:
- Discontinuation/reduction may improve renal recovery (OR 3.47) but results in less efficient decongestion 7
- Persistent congestion consistently predicts worse prognosis regardless of creatinine changes 4
- Transient creatinine increases during effective decongestion are NOT independently associated with adverse outcomes when congestion resolves 4
Practical Approach:
- Prioritize achieving complete decongestion over avoiding creatinine increases
- Adjust dose based on congestion status, not creatinine alone
- Monitor for true volume depletion versus pseudo-worsening renal function from decongestion
Common Pitfalls to Avoid
Anticipatory Discontinuation: 24% of patients had medications stopped without documented creatinine rise, based only on anticipated deterioration 8. This practice lacks evidence support.
Confusing Decongestion-Related Creatinine Rise with True AKI: Creatinine increases during effective decongestion often reflect improved hemodynamics, not kidney injury 4.
Ignoring Mortality Risk: The composite treatment score >1 (multiple medication discontinuations) was associated with 71% increased 6-month mortality (HR 1.71) 7.
Failure to Restart: Nearly 50% of elderly patients never restart RAS blockers after AKI, leading to increased long-term mortality 9, 10.
Reinitiation Strategy
Timing for Restart:
- When GFR has stabilized (not necessarily returned to baseline)
- Volume status is optimized
- Hemodynamics are stable 3
Evidence: Reinitiation of RASi after AKI and hyperkalemia is associated with improved survival and reduced CKD progression 10. The ADQI consensus recommends personalized risk-benefit assessment rather than blanket discontinuation 3.
Monitoring Requirements
When continuing GDMT during AKI:
- Check renal function and electrolytes at 1 and 4 weeks after any dose change 6
- Assess congestion status clinically (not just by creatinine)
- Monitor blood pressure for symptomatic hypotension (not arbitrary thresholds)
- Regular potassium monitoring, especially with MRAs
The overarching principle: True contraindications to GDMT are rare 1. The default should be continuation with close monitoring, not reflexive discontinuation, as the mortality cost of stopping these medications typically exceeds the risk of continuing them through AKI.